In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Mallinckrodt plc. Trade Record

NYSE:MNK Mallinckrodt plc stock gains 76.68% Exit Aug 30, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart MNK Jul 5, 2018, priceSeries
About Mallinckrodt plc

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded and generic specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. The company's Specialty Brands segment markets branded pharmaceutical products for autoimmune and rare diseases, including the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and hemostasis products, and central nervous system drugs. This segment offers Acthar, an injectable drug for various indications, such as neurology, rheumatology, nephrology, and pulmonology; Ofirmev, an intravenous formulation of acetaminophen for pain management; Inomax for inhalation; Therakos, an immunotherapy treatment platform; and Exalgo, a form of hydromorphone. It is also developing StrataGraft, a full-thickness product for severe burns and other complex skin defects. Its Specialty Generics segment provides specialty generic pharmaceuticals and active pharmaceutical ingredients (APIs) consisting of hydrocodone and hydrocodone-containing tablets; oxycodone and oxycodone-containing tablets; methylphenidate HCl extended-release tablets; and other controlled substances, including acetaminophen products. The company markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. It distributes its branded and generic products through independent channels, including wholesale drug distributors, specialty pharmaceutical distributors, retail pharmacy chains, hospital networks, ambulatory surgical centers, and governmental agencies; and APIs directly or through distributors to other pharmaceutical companies. Mallinckrodt public limited company is based in Chesterfield, the United Kingdom.

Trade Information
Trade Type
LONG
ReliabilityScore™
95.38
Entry Date
Jul 5, 2018
Entry Price
19.27
Sell Date
Aug 30, 2018
Sell Price
34.05
Net Gain
76.68%
Hold Time
40 Trading Days